Clear all

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

971 results found

Article
Ask Lexy

Fenwick & West LLP | USA | 18 Nov 2021

2021 Proxy Season Results in Silicon Valley and at Large Companies Nationwide

Shareholder activism has been a significant phenomenon amongst the largest U.S. public companies, with activists of a variety of stripes waging…
Article
Ask Lexy

Pearce IP | Australia | 8 Nov 2021

Pearce IP BioBlast®: w/e 05 November 2021

The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to…
Article
Ask Lexy

Venable LLP | USA | 8 Nov 2021

Venable Fitzpatrick’s BiologicsHQ Monthly Injection - October 2021

On October 15, 2021, the FDA approved Boehringer Ingelheim's Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie's Humira® (adalimumab)…
Article
Ask Lexy

Venable LLP | USA | 25 Oct 2021

FDA Approves Boehringer Ingelheim’s Cyltezo® as Interchangeable with Humira®

On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for…
Article
Ask Lexy

Crowell & Moring LLP | USA | 25 Oct 2021

AbbVie Trade Secret Claims Fail at Pleading Stage for Lack of Jurisdiction

In March 2021, AbbVie, Inc. and AbbVie Biotechnology Ltd. (“AbbVie”) sued rival pharmaceutical company Alvotech hf. (“Alvotech”) for trade secret…
Article
Ask Lexy

Pearce IP | Australia | 18 Oct 2021

Pearce IP BioBlast®: w/e 15 October 2021

Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of…
Article
Ask Lexy

Pearce IP | Australia | 11 Oct 2021

Pearce IP BioBlast®: w/e 08 October 2021

Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of…
Article
Ask Lexy

Pearce IP | Australia | 5 Oct 2021

Pearce IP BioBlast®: w/e 01 October 2021

Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million…
Article
Ask Lexy

Pearce IP | Australia | 27 Sep 2021

Pearce IP BioBlast®: w/e 24 September 2021

Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically…
Article
Ask Lexy

Osler Hoskin & Harcourt LLP | Canada | 24 Sep 2021

The impact of CAR T cell patenting on access to therapy in Canada

Typically, when launching a new therapy, such as a drug or biologic, the sponsor of the therapy attempts to obtain broad patent protection to prevent…
Previous page 1 2 3 ...